» Articles » PMID: 31875891

Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases

Overview
Date 2019 Dec 27
PMID 31875891
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The emergence of biosimilars is generally considered as an opportunity to guarantee accessibility to affordable treatments and to enhance financial sustainability of national health systems. Since 2017, five biosimilars of adalimumab were approved by the European Medicines Agency [EMA] for use in inflammatory bowel disease: ABP 510, SB5, GP2017, FKB327, and MSB11022. In this position statement, the available efficacy and safety data of the different adalimumab biosimilars in immune-mediated inflammatory diseases are summarised. Furthermore, the Belgian IBD research group [BIRD] formulates statements concerning the use of adalimumab biosimilars in inflammatory bowel disease.

Citing Articles

The Efficacy, Safety, and Persistence of Therapy after Non-Medical Switching from an Originator Adalimumab in Inflammatory Bowel Disease: Real-Life Experience from Two Tertiary Centres.

Spataru T, Popescu R, State M, Pahomeanu M, Mateescu B, Negreanu L Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458960 PMC: 11510052. DOI: 10.3390/ph17101319.


Navigating adalimumab biosimilars: an expert opinion.

Abitbol V, Benkhalifa S, Habauzit C, Marotte H J Comp Eff Res. 2023; 12(11):e230117.

PMID: 37855223 PMC: 10690439. DOI: 10.57264/cer-2023-0117.


Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking.

Barbier L, Simoens S, Declerck P, Vulto A, Huys I Front Pharmacol. 2022; 13:821616.

PMID: 35903323 PMC: 9315422. DOI: 10.3389/fphar.2022.821616.


Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.

Derikx L, Dolby H, Plevris N, Lucaciu L, Rees C, Lyons M J Crohns Colitis. 2021; 15(12):2011-2021.

PMID: 34089587 PMC: 8684477. DOI: 10.1093/ecco-jcc/jjab100.